Format

Send to

Choose Destination
Gastroenterol Hepatol (N Y). 2016 Dec;12(12):741-751.

The Role of Biosimilars in Inflammatory Bowel Disease.

Author information

1
Dr Paramsothy is an advanced IBD fellow, Dr Krugliak Cleveland is an internal medicine resident, Dr Zmeter is a clinical research coordinator, and Dr Rubin is a professor of medicine at the Inflammatory Bowel Disease Center at the University of Chicago Medicine in Chicago, Illinois.

Abstract

Monoclonal antibody biologic therapies, introduced nearly 20 years ago, revolutionized the treatment of inflammatory bowel disease (IBD) and are now well established as the most effective agents available. As the first of these biologic agents starts to come off patent, biosimilar agents have emerged as alternatives to originator drugs. The unique drug development and manufacturing processes involved in the creation of biologic agents pose distinct regulatory challenges compared to generic formulations of conventional medications. Reductions in medication costs have been proposed to be a major benefit of biosimilar therapies; however, there are concerns regarding the adequacy of the existing regulatory process and data requirements for biosimilar therapy approval, as well as the true bioequivalence of these agents. Infliximab biosimilars for the treatment of IBD have been available in Europe and Asia for a few years and are expected to become available in the United States within the next 1 to 2 years. This article reviews biosimilar therapies and the current data with respect to IBD.

KEYWORDS:

Biosimilar; Crohn’s disease; biologic; inflammatory bowel disease; ulcerative colitis

PMID:
28035201
PMCID:
PMC5193082

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center